Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 8/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL334878 | 0.83 | RAB9A (0.60) | RAB9AMAPTNPC1LMNASMN1; SMN2 | |
| SCHEMBL574340 | 0.83 | MAPT (0.55) | RAB9AMAPTNPC1LMNASMN1; SMN2 | |
| SCHEMBL10367557 | 0.80 | MAPT (0.53) | RAB9AMAPTNPC1LMNASMN1; SMN2 | |
| SCHEMBL10367558 | 0.80 | MAPT (0.53) | RAB9AMAPTNPC1LMNASMN1; SMN2 | |
| SCHEMBL8027680 | 0.79 | MAPT (0.54) | RAB9AMAPTNPC1LMNASMN1; SMN2 | |
| SCHEMBL8027893 | 0.79 | SMN1; SMN2 (0.54) | RAB9AMAPTNPC1LMNASMN1; SMN2 | |
| SCHEMBL28234 | 0.79 | KDM4E (0.53) | RAB9AMAPTNPC1LMNASMN1; SMN2 | |
| SCHEMBL3268052 | 0.77 | RAB9A (0.66) | RAB9AMAPTNPC1LMNASMN1; SMN2 | |
| SCHEMBL5586004 | 0.77 | RAB9A (0.60) | RAB9AMAPTNPC1LMNASMN1; SMN2 | |
| SCHEMBL10879313 | 0.77 | RAB9A (0.60) | RAB9AMAPTNPC1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0254222-B1 | QUINOLINOXY COMPOUNDS, PROCEDURE FOR THEIR SYNTHESIS AND THEIR APPLICATION AS ANTIDOTES | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-08-26 | — | — | EP | claimed |
| EP-1330460-B1 | BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE | SMITHKLINE BEECHAM PLC (GB) | 2007-03-21 | — | — | EP | disclosed |
| US-6939871-B2 | Benzoxazinone derivatives, their preparation and use | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-09-06 | — | — | US | disclosed |
| US-20040063704-A1 | Benzoxazinone derivatives, their preparation and use | SMITHKLINE BEECHAM P.L.C (GB) | 2004-04-01 | — | — | US | disclosed |
| EP-1330460-A2 | BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE | SMITHKLINE BEECHAM PLC (GB) | 2003-07-30 | — | — | EP | disclosed |
| WO-2002034754-A2 | BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-05-02 | — | — | WO | disclosed |
| EP-0254222-B1 | QUINOLINOXY COMPOUNDS, PROCEDURE FOR THEIR SYNTHESIS AND THEIR APPLICATION AS ANTIDOTES | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063704-A1 | Benzoxazinone derivatives, their preparation and use | CYP2B6, CBR1, CYP2A6 | RAB9A 2894/4885MAPT 4878/4885NPC1 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.